Coronavirus Infection
Conditions
Keywords
coronavirus infections, SARS-CoV-2, COVID-19, ivermectin, clinical trial
Brief summary
In December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.
Interventions
DRUGIvermectin
SOC plus different dosing regimens of Ivermectin
OTHERStandard of Care
Standard treatment for COVID-19
Sponsors
Universidade Federal de Sao Carlos
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of infection by SARS-CoV-2: 1. symptoms of acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS-CoV-2 infection; OR 2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection; OR 3. severe acute respiratory infection (fever and at least one sign / symptom of respiratory disease eg cough, fever, shortness of breath) AND in need of hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection; * Eastern Cooperative Oncology Group Performance Status score 0 to 1; * National Early Warning Score 0 to 4; * Ability to understand and consent to participate in this clinical trial, manifested by signing the Informed Consent Form (ICF).
Exclusion criteria
* Inability to ingest / absorb the study drug orally through spontaneous ingestion or use of gastro / enteral tubes; * Any finding of clinical observation (history / physical evaluation) that is interpreted by the investigating physician as a risk to participate in the trial; * Any laboratory test findings that the investigating physician considers as a risk to the research participant as to his / her participation in the clinical study; * Any ECG examination finding that the investigating physician considers as a risk to the research participant as to his / her participation in the trial; * Known hypersensitivity to the components of the drugs used during the study; * Women in pregnancy or breastfeeding; * Body weight less than 15kg; * Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) \<30 mL / min; * Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)\> 5 times the upper limit of normality; * Refusal to participate; * Refusal to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Undetectable viral load during 7 days of follow-up. | 7 days following intervention | Proportion of patients who achieved undetectable viral load during 7 days of follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Viral load variation in the nasopharyngeal swab. | 7 days following intervention. | Viral load variation in the nasopharyngeal swab during treatment. |
| Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab. | 7 days following intervention. | Variation of serum lymphocyte counts during treatment. |
| Incidence of Treatment-Emergent Self-reported Adverse Events | 28 days following intervention. | Incidence of Treatment-Emergent Adverse Events as assessed by clinical history and physical examination |
| Incidence of Treatment-Emergent Laboratory-based Adverse Events | 28 days following intervention. | Incidence of Treatment-Emergent Adverse Events as assessed by laboratory tests |
Countries
Brazil
Outcome results
None listed